[{"orgOrder":0,"company":"Nuwacell Biotechnologies","sponsor":"Shanghai 6th People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NCR100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Nuwacell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nuwacell Biotechnologies \/ Shanghai 6th People's Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Nuwacell Biotechnologies \/ Shanghai 6th People's Hospital"},{"orgOrder":0,"company":"Nuwacell Biotechnologies","sponsor":"Shanghai 6th People's Hospital | Beijing Luhe Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"NCR100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Nuwacell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nuwacell Biotechnologies \/ Shanghai 6th People's Hospital | Beijing Luhe Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Nuwacell Biotechnologies \/ Shanghai 6th People's Hospital | Beijing Luhe Hospital"},{"orgOrder":0,"company":"Nuwacell Biotechnologies","sponsor":"The First Affiliated Hospital of University of Science and Technology of China","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"NCR300","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Nuwacell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nuwacell Biotechnologies \/ The First Affiliated Hospital of University of Science and Technology of China","highestDevelopmentStatusID":"6","companyTruncated":"Nuwacell Biotechnologies \/ The First Affiliated Hospital of University of Science and Technology of China"},{"orgOrder":0,"company":"Nuwacell Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"NCR101","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Nuwacell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nuwacell Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nuwacell Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Nuwacell Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"NCR102","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Nuwacell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nuwacell Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nuwacell Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Nuwacell Biotechnologies","sponsor":"Beijing Friendship Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NCR300","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Nuwacell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nuwacell Biotechnologies \/ Beijing Friendship Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Nuwacell Biotechnologies \/ Beijing Friendship Hospital"},{"orgOrder":0,"company":"Nuwacell Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Human Induced Pluripotent Stem Cell Derived Natural Killer Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Nuwacell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nuwacell Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nuwacell Biotechnologies \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Nuwacell Biotechnologies

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pipeline prospector

Contact Supplier

Check all FDF Dossiers for
this supplier

Contact Us
PharmaScopic.com

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Nuwacell Biotechnologies

China

Vitafoods

Not Confirmed

02

Nuwacell Biotechnologies

China

Vitafoods

Not Confirmed

03

Nuwacell Biotechnologies

China

Vitafoods

Not Confirmed

04

Nuwacell Biotechnologies

China

Vitafoods

Not Confirmed

05

Nuwacell Biotechnologies

China

Vitafoods

Not Confirmed

06

Nuwacell Biotechnologies

China

Vitafoods

Not Confirmed

07

Nuwacell Biotechnologies

China

Vitafoods

Not Confirmed